Bragar Eagel & Squire, P.C. Is Investigating Trinity Biotech plc (TRIB) on Behalf of Stockholders & Encourages Investors to C...
January 05 2017 - 5:30PM
Business Wire
Bragar Eagel & Squire, P.C. is investigating potential
claims against Trinity Biotech plc (NASDAQ:TRIB) concerning
possible violations of the federal securities laws.
On October 4, 2016, Trinity revealed that it was withdrawing its
510(k) premarket notification submission for the Meritas Troponin-I
Test and Meritas Point-of-Care Analyzer, following the U.S. Food
and Drug Administration’s advice. Trinity also said it would
decrease its spending by roughly 85%, from $9 million each year to
$1.5 million, and that it would close its Swedish facility,
eliminating 40 jobs. Following this news, Trinity shares dropped
$6.53 per share to close at $6.46 on October 4, 2016.
If you purchased or otherwise acquired Trinity securities and
suffered a loss, have information or would like to learn more about
these claims, or have any questions concerning this announcement or
your rights or interests with respect to these matters, please
contact J. Brandon Walker, Esq. by email at
investigations@bespc.com, or telephone at (212) 355-4648, or by
filling out this contact form. There is no cost or obligation to
you.
Bragar Eagel & Squire, P.C. is a New York-based law firm
concentrating in commercial and securities
litigation. For additional information concerning our
investigation into Trinity Biotech plc, please go to
www.bespc.com/trinity-biotech-plc. For additional
information about Bragar Eagel & Squire, P.C., please go to
www.bespc.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170105006478/en/
Bragar Eagel & Squire, P.C.J. Brandon Walker, Esq.,
212-355-4648investigations@bespc.comwww.bespc.com
Trinity Biotech (NASDAQ:TRIB)
Historical Stock Chart
From Aug 2024 to Sep 2024
Trinity Biotech (NASDAQ:TRIB)
Historical Stock Chart
From Sep 2023 to Sep 2024